平衡风险完整性指数（BRII）：竞争风险与删失下评估临床预测警报的分层指标

Abstract

Background: Conventional discrimination metrics, such as the area under the receiver operating characteristic curve (AUROC), do not characterize the composition of outcomes among patients flagged as high risk by clinical prediction models. This limitation is particularly relevant in critical care, where competing deaths and incomplete follow-up can complicate the interpretation of prediction alerts. We developed the Balanced Risk Integrity Index (BRII), a stratum-level metric defined as the proportion of target events among target events, competing deaths, and early-censored observations in a flagged high-risk stratum. BRII is algebraically related to positive predictive value (PPV) and is reported alongside its component decomposition to characterize the outcome composition of flagged patients. Methods: We evaluated BRII using seven acute kidney injury (AKI) prediction models developed in MIMIC-IV and externally validated in MIMIC-III and eICU-CRD (116,010 patients in total). Additional simulations examined the effects of competing deaths and early censoring on BRII and conventional model performance metrics. Results: For 48-hour AKI prediction in the top 10% risk stratum, BRII ranged from 0.90 to 0.96 in MIMIC-III, compared with less than 0.26 across all models in eICU-CRD, where 61.5% of evaluated patients were censored before the prediction horizon. In the eICU-CRD top 10% strata for the same target, 37.0% to 50.2% of patients were censored early, 12.2% to 15.5% had AKI, and 3.4% to 8.1% died before AKI. BRII and PPV ordered at least one model pair differently in 34 of 48 cohort-outcome-top-k groups. Under simulated random censoring for 48-hour AKI prediction, BRII declined by up to 0.80 while binary-label AUROC changed by less than 0.02. Conclusions: BRII provided complementary information on high-risk stratum composition, yielding different model rankings from PPV and revealing substantial differences across external validation cohorts. Interpreted alongside PPV and its component decomposition, BRII offers a standardized approach to evaluating clinical prediction alerts across models and observation environments.

Competing Interest Statement

The authors have declared no competing interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All databases contain de-identified data. Use of these data is exempt from institutional review board approval under 45 CFR 46.101(b)(4). Access was obtained through PhysioNet Credentialed Health Data Use Agreements.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

MIMIC-IV, MIMIC-III, and eICU-CRD are publicly available through PhysioNet (https://physionet.org). Source data for all figures and tables are provided with this paper.

Funder Information Declared

Institute of Information & Communications Technology Planning & Evaluation, IITP-2026-RS-2022-00156439

National Research Foundation of Korea, RS-2026-25477844